BMN 270: A Big Valuation Catalyst for BioMarin

On March 1, 2016, BioMarin received orphan drug designation for BMN 270 from the FDA. BioMarin’s stock jumped by about 6.96% the same day.

Jillian Dabney - Author

Nov. 20 2020, Updated 12:41 p.m. ET

uploads///Graph pipeline

Orphan drug designation for BMN 270

On March 1, 2016, BioMarin Pharmaceutical (BMRN) received orphan drug designation for BMN 270 from the FDA (US Food and Drug Administration). Following this news, BioMarin’s stock jumped by about 6.96% the same day.

The valuation of a biotechnology company is subject to the number of products in its pipeline, their development stage, and the historical clinical trial success rate of the company. And BioMarin holds a robust research pipeline.

Article continues below advertisement
Article continues below advertisement

Update on BMN 270 study

BMN 270 is a pipeline gene therapy indicated for hemophilia A. The drug is AAV-factor VIII vector, with a market opportunity of more than $1 billion. There are ~90,000 patients in BioMarin’s commercial territories.

Currently, BioMarin is conducting phase 1/2 trial to access safety and efficacy of the therapy in up to 12 patients. The company is treating the patients with third dose level, which is ten times higher than the starting dose.

Gene therapy and hemophilia A

Hemophilia A is a factor VIII (FVIII) deficiency disorder. Gene therapy fixes the defective gene with the corrected copy. There is no approved gene therapy to treat hemophilia. But many companies are conducting research on gene therapy for the condition. For example, Biogen (BIIB) is evaluating gene therapy for hemophilia in collaboration with Sangamo Biosciences (SGMO), while Baxalta (BXLT), Dimension Therapeutics (DMTX), and Pfizer (PFE) are all conducting their own research on gene therapy for hemophilia.

We should note here that stock prices are susceptible to company-, industry-, and economy-specific events. So to get exposure to BioMarin Pharmaceuticals and control excessive company-specific risks, investors can choose to invest in the iShares Nasdaq Biotechnology ETF (IBB). BioMarin accounts for about 2.7% of IBB’s total holdings.

For ongoing analysis, keep checking in with Market Realist’s Pharmaceuticals page.


Latest iShares Nasdaq Biotechnology ETF News and Updates

    Opt-out of personalized ads

    © Copyright 2024 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.